This week, pharma and medical imaging startup and Verve Ventures portfolio company MedTrace Pharma A/S announced the appointment of Nicholas Borys, M.D. as Chief Medical Officer (CMO). Dr Borys has extensive global experience in leading clinical research and drug development programs for innovative therapies and diagnostics in cardiology, oncology, neurology, and nuclear medicine. He has spent 15 years as Executive Vice President and CMO at the Nasdaq-listed pharma company IMUNON and now joins MedTrace after having spent the last two years as a Consulting Chief Medical Officer at NB&C Consulting. At MedTrace he will be responsible for the successful completion of the company’s Phase III Clinical Trial. Read the full press release: https://lnkd.in/dMQvTvRP #newhire #startupnews #health #medtech #medicalimaging #pharma
Verve Ventures
Wagniskapital- und Private-Equity-Auftraggeber
Zürich, Zürich 30.897 Follower:innen
Investing in technology and science driven startups. Adding value through our exclusive network of investors.
Info
Verve Ventures is a network and technology-driven venture capital firm headquartered in Switzerland. Founded in 2010, Verve Ventures has grown to more than 45 team members and has become one of the most active venture investors in Europe with over 140 technology and science-driven startups in its portfolio. A dozen investment professionals identify the most promising digital, tangible and health & bio startups. Verve Ventures provides it’s pan-European network of selected private and institutional investors access to those top tier investment opportunities. The company invests from EUR 500k to several million from Seed to Series B and beyond across Europe. Verve Ventures’ dedicated team helps startups with their most pressing needs such as hiring, client introductions and access to an expert network of high-profile individuals. To become part of Verve Ventures’ growing network of entrepreneurs and investors, visit verve.vc.
- Website
-
https://www.verve.vc/
Externer Link zu Verve Ventures
- Branche
- Wagniskapital- und Private-Equity-Auftraggeber
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Zürich, Zürich
- Art
- Privatunternehmen
- Gegründet
- 2010
- Spezialgebiete
- Deal sourcing (early stage), Due Diligence, Deal structuring, Investment facilitation, Risikokapital und Business Angel
Orte
-
Primär
Brandschenkestrasse 90
Zürich, Zürich 8002, CH
-
Oberdorfstrasse 38
Baar, 6340, CH
Beschäftigte von Verve Ventures
Updates
-
Last week, Verve Ventures Principal Romeo Bütler emphasized the crucial need for the investor ecosystem to grasp the multifaceted value of water during the Investing in Water Innovation session organized by UpLink - World Economic Forum. Hosted by Anna Huber, Project Lead Innovation Ecosystems at UpLink, and featuring insights from UpLink Aquapreneur Catalina Pfenniger, Strategy Director at Kran Nanobubble, and Kelven Lam, Investment Manager at Emerald Technology Ventures, the session delved into the untapped potential of water innovation investment. Watch the full session: https://lnkd.in/d-KSAAUz #waterinnovation #investmentopportunities #sustainability #water #innovation
🌊 Romeo Bütler, Principal at Verve Ventures, underscored the need for the investor ecosystem to understand the multifaceted value of #water, during our 'Investing in Water Innovation' session last week. Hosted by Anna Huber, Project Lead Innovation Ecosystems at UpLink, and also featuring UpLink Aquapreneur Catalina Pfenniger, Strategy Director at Kran Nanobubble and Kelven Lam, Investment Manager at Emerald Technology Ventures, the session explored the overlooked potential of water innovation investment. 👉 Watch the session in full on UpLink: https://ow.ly/cNBs50ToTJ8 HCLTech HCL Enterprise #WaterInnovation #ImpactInvesting #ClimateTech #NatureTech #SDG6
-
Spine surgery specialist and Verve Ventures portfolio company Neo Medical announced today the successful closing of its Series B financing round, including the conversion of existing shareholder loans. With this financing round, Neo has secured an additional equity investment of up to USD 68 million to accelerate its global growth. The round was led by Gyrus Capital, alongside the participation of existing investors, including Verve Ventures and Neo founders Vincent Lefauconnier and Jonas Larsson. This landmark round is one of the most significant in the spine industry in the last decade. Congratulations to the whole Neo team! The proceeds will be used to increase Neo’s market share in key regions with an immediate focus on expanding the US business, deploying new, complementary, and disruptive products, and enhancing the capabilities of its unique AI-driven augmented reality intraoperative data platform, ADVISE™. Read the full press release: https://lnkd.in/dqv-jbZa #fundingnews #health #spinesurgery #surgery #medicaldevices #startupnews
-
Julien Pache, Partner at Verve Ventures, recently joined Guenter Jaeger and Aurelia Rauch on Bergos AG's BERPLEXED podcast to discuss the evolving landscape of venture capital in the age of AI. Julien shared his insights on how VCs are adapting their strategies in the wake of AI’s rise, and balancing excitement with caution. 🎧 Listen now: https://lnkd.in/dgskHytt On Spotify: https://lnkd.in/dTzCd_tw #AI #venturecapital #innovation #podcast #techtrends #technology #investment #BERPLEXED
-
Our portfolio company CREAL recently announced a license agreement with ZEISS Group to create a digitized vision care platform aimed at revolutionizing current diagnostic and treatment procedures. By integrating CREAL's light field display into vision test devices, ZEISS plans to introduce a groundbreaking solution for precise digital diagnosis of eye defects. By replicating real-world light to create digital images with authentic depth, CREAL’s true 3D display will enable the digital replication of any physical or theoretical lens, allow vision tests to be tailored to specific age groups or customer segments, and project automated content, reducing the overall need for clinical resources. Read the full press release: https://lnkd.in/etfh7XyK #zeiss #creal #optometry #visiontesting #vision #digitaldiagnosis #eyecare #startupnews
-
Our portfolio company Puraffinity, the start-up developing precision technologies which remove toxic “forever chemicals” (PFAS) from water, announced today the appointment of Vincent Caillaud as its new CEO. Vincent brings exceptional industry experience, with more than 20 years working in the water treatment sector. He was previously CEO of Veolia Water Technologies & Solutions (10,000 employees, $3bn revenue), a global water technology business unit within the world’s largest water, energy and waste management company, Veolia. Founder Henrik Hagemann will transition into the role of Chief Product and Innovation Officer, focusing on advancing the company's product roadmap, innovation and strategy to meet evolving market needs. Puraffinity also announced it has secured a £6.7 million investment from BGF, bringing their Series A funding round up to £16.93 million. Read the full press release: https://lnkd.in/e-_VkW22 #newceo #ceo #ceonews #startupnews #fundingnews #PFAS #startup #investment
-
The use of injections in treatments is widespread, but their use can become a burden to patients and severely impact their quality of life. Biograil™ is working on an innovative delivery mechanism for biological drugs that could offer a valuable alternative to injections. In this interview, Karsten Lindhardt, the company’s CEO and founder, reveals how Biograil’s extensive experience, strategic partnerships and innovative approach will help them deliver and scale a market-ready product that will transform drug delivery and improve the lives of patients worldwide. Read the full interview: https://lnkd.in/dDMjYrVu #biograil #health #pharma #pharmaceuticals #entrepreneurship #startup #interview #drugdelivery
-
Our portfolio company IRUBIS announced today the successful closing of its pre-series A funding round. The financing round was led by BioProcess360 Partners, with participation from previous investors such as Verve Ventures, HTGF | High-Tech Gründerfonds, Ventura BioMed Investors, RoBet KG as well as new and existing business angels from the industry such as Dr. Matthias Arnold and Dr. Christoph Bremus. IRUBIS is a deep tech startup that has developed an inline spectrometer system to enhance biopharmaceutical production efficiency. Currently, nutrient levels in bioreactors are manually sampled and analyzed, which is time-consuming and poses contamination risks. IRUBIS’ device continuously monitors nutrient and metabolite levels inline, allowing for automatic optimization, faster process development, and higher yields. The core of their technology is ATR (attenuated total reflection) crystals made from silicon, which are 100 times cheaper than the conventional diamond crystals. The raised funds will further enhance IRUBIS’s cutting-edge solution, Monipa, tailored to empower bioprocesses with increased efficiency and precision. Read the full press release: https://lnkd.in/d3ZeuYJi #health #fundingnews #biotech #pharma #technology #bioprocessing #biopharma
-
At Verve Ventures, we believe that technology plays an important role in addressing some of humanity's greatest challenges. In the climate space, we’re committed to driving fundamental innovation that not only reduces our future impact but also mitigates the effects of past actions. This Wednesday, 28 August, Thomas Meier, Principal at Verve Ventures, will share insights into our climate and energy thesis in our latest webinar. Thomas will discuss key trends in this space and explore how the financing landscape for climate tech startups is evolving. Thomas is a seasoned investor with a focus on climate and energy. At Verve, he has spearheaded investments in innovative companies like Climeworks, tozero, Neustark, Turn2X and Bcomp. He brings a wealth of experience from his work with Yttrium, Fraunhofer Venture, and Bain & Company, along with academic credentials from top institutions such as KIT, TUM, and HEC Paris. 📅 Wednesday, 28 August 📍 Register today: https://lnkd.in/dyhNarUS #climatetech #innovation #investment #webinar #deeptech #sustainability #climate
-
Verve Ventures hat dies direkt geteilt
In June 2024, carbon removal startup neustark raised USD 69 million in a growth equity round led by Decarbonization Partners, a partnership between BlackRock and Temasek. Verve Ventures also participated in the round and has been an investor in neustark since 2023. An ETH-spin-off, neustark has developed a process that stores CO2 permanently and efficiently in demolition concrete. Concrete recyclers can seamlessly integrate the so-called mineralization technology within their existing operations. The resulting carbonated concrete aggregate is reused to produce fresh, recycled concrete or as a base layer for road construction. In this interview, co-founder and co-CEO Johannes Tiefenthaler talks about the company's plans to double their number of employees and expand across Europe in the next 12 months to support the scale-up’s ambition of permanently removing 1 million tons of CO2 in 2030. Read the full interview: https://lnkd.in/d2ubx_Zh #neustark #carbonremoval #concrete #concreterecycling #climatetech #climateimpact #entrepreneurship #entrepreneurinterview #interview #technology